DDD alterations from 2005-2024
Cumulative overview of all DDD alterations performed in the period 2005-2024. The year changed is when the alterations were implemented in the ATC/DDD Index. Please note that a DDD may have changed more than once for some ATC codes. The ATC codes are current codes. For substances where the DDD is changed twice the new DDD which is not according to current value is marked with an asterix (*).
List of abbrevations
| Substance | Previous DDD | New DDD* | Present ATC code | Year changed | |||||
|---|---|---|---|---|---|---|---|---|---|
| alosetron | 2 | mg | O | 1 | mg | O | A03AE01 | 2005 | |
| amoxicillin and beta-lactamase inhibitor | 1 | g | O | 1.5 | g | O | J01CR02 | 2019 | |
| amoxicillin and enzyme inhibitor | 1 | g | P | 3 | g | P | J01CR02 | 2005 | |
| amoxicillin | 1 | g | O | 1.5 | g | O | J01CA04 | 2019 | |
| amoxicillin | 1 | g | P | 3 | g | P | J01CA04 | 2019 | |
| ampicillin and enzyme inhibitor | 2 | g 3) | P | 6 | g 3) | P | J01CR01 | 2017 | |
| ampicillin | 2 | g | P | 6 | g | P | J01CA01 | 2019 | |
| amprenavir | 2.4 | g | O | 1.2 | g | O | J05AE05 | 2006 | |
| apixaban | 5 | mg | O | 10 | mg | O | B01AF02 | 2016 | |
| aprepitant 5) | 95 | mg | P | 150 | mg | P | A04AD12 | 2019 | |
| aprepitant | 95 | mg | O | 165 | mg | O | A04AD12 | 2019 | |
| atorvastatin | 10 | mg | O | 20 | mg | O | C10AA05 | 2009 | |
| baricitinib | 4 | mg | O | 3 | mg | O | L04AA37 | 2023 | |
| blood coagulation factors | 1 | deleted 2) | B02BD | 2017 | |||||
| budesonide | 2 | mg | SL | 1.5 | mg | SL | A07EA06 | 2024 | |
| calcium acetate | 2 | g | O | 6 | g | O | V03AE07 | 2017 | |
| calcium chloride | 0.2 | g | P | deleted 6) | A12AA07 | 2023 | |||
| calcium glubionate | 2.75 | g | P | deleted 6) | A12AA02 | 2023 | |||
| calcium gluconate | 3 | g | P | deleted 6) | A12AA03 | 2023 | |||
| calcium laevulate | 1 | g | P | deleted 6) | A12AA30 | 2023 | |||
| cefepime | 2 | g | P | 4 | g | P | J01DE01 | 2019 | |
| ceftezole | 6 | g | P | 3 | g | P | J01DB12 | 2008 | |
| ciprofloxacin | 0.5 | g | P | 0.8 | g | P | J01MA02 | 2019 | |
| colistin | 3 | MU | P | 9 | MU | P | J01XB01 | 2019 | |
| dabigatran etexilate | 0.22 | g | O | 0.3 | g | O | B01AE07 | 2016 | |
| daclizumab | 0.35 | g | P | 5 | mg | P | L04AC01 | 2018 | |
| desmopressin | 0.36 | mg 1) | SL | 0.24 | mg 1) | SL | H01BA02 | 2009 | |
| esomeprazole | 20 | mg | O | 30 | mg | O | A02BC05 | 2005 | |
| fentanyl | 0.6 | mg | TD | 1.2 | mg | TD | N02AB03 | 2005 | |
| fluvastatin | 40 | mg | O | 60 | mg | O | C10AA04 | 2009 | |
| gliclazide | 0.16 | g | O | 60 | mg | O | A10BB09 | 2011 | |
| glycopyrronium bromide | 3 | mg | P | 0.3 | mg | P | A03AB02 | 2018 | |
| human menopausal gonadotrophin | 30 | U | P | 75 | U | P | G03GA02 | 2016 | |
| ibrandronic acid | 5 | mg | P | 6 | mg | P | M05BA06 | 2007 | |
| levetiracetam | 2 | g | O | 1.5 | g | O | N03AX14 | 2005 | |
| liraglutide | 1.2 | mg | P | 1.5 | mg | P | A10BJ02 | 2020 | |
| lovastatin | 30 | mg | O | 45 | mg | O | C10AA02 | 2009 | |
| magnesium chloride | 0.8 | g | P | deleted 6) | A12CC01 | 2023 | |||
| magnesium sulfate | 1 | g | P | deleted 6) | A12CC02 | 2023 | |||
| meropenem | 2 | g | P | 3 | g | P | J01DH02 | 2019 | |
| mifepristone | 0.6 | g | O | 0.2 | g | O | G03XB01 | 2017 | |
| posaconazole | 0.8 | g | O | 0.3 | g | O | J02AC04 | 2017 | |
| pravastatin | 20 | mg | O | 30 | mg | O | C10AA03 | 2009 | |
| risperidone | 1.8 | mg | P depot | 2.7 | mg | P depot | N05AX08 | 2010 | |
| rivaroxaban | 10 | mg | O | 20 | mg | O | B01AF01 | 2016 | |
| simvastatin | 15 | mg | O | 30 | mg | O | C10AA01 | 2009 | |
| sirolimus | 6 | mg | O | 3 | mg | O | L04AA10 | 2006 | |
| sodium selenite | 0.2 | mg | P | deleted 6) | A12CE02 | 2023 | |||
| temocillin | 2 | g | P | 4 | g | P | J01CA17 | 2019 | |
| thioctic acid | 0.2 | g | O,P | 0.6 | g | O,P | A16AX01 | 2017 | |
| tiotropium bromide | 18 | mcg 4) | Inhal. powder | 10 | mcg 4) | Inhal. powder | R03BB04 | 2017 | |
| vasopressin (argipressin) | 4 | U | P | 40 | U | P | H01BA01 | 2019 | |
1) Base.
2) DDDs for the various blood coagulation factors in all ATC 5th level codes in B02BD are deleted. No new DDDs will be established in B02BD Blood coagulation factors.
3) Refers to ampicillin.
4) The DDD for tiotropium bromide is unchanged but has been defined as the content of one inhalation capsule (18 mcg) as tiotropium. Since there are different inhalation capsules on the market containing different amounts of active substance, the DDD is now defined as the delivered dose, which is the same (10 mcg) as tiotropium for all products.
5) Refers to fosaprepitant
6) Parenteral DDDs in A12 are deleted. All parenteral solutions of electrolytes should be classified in B05B or in B05X.
2) DDDs for the various blood coagulation factors in all ATC 5th level codes in B02BD are deleted. No new DDDs will be established in B02BD Blood coagulation factors.
3) Refers to ampicillin.
4) The DDD for tiotropium bromide is unchanged but has been defined as the content of one inhalation capsule (18 mcg) as tiotropium. Since there are different inhalation capsules on the market containing different amounts of active substance, the DDD is now defined as the delivered dose, which is the same (10 mcg) as tiotropium for all products.
5) Refers to fosaprepitant
6) Parenteral DDDs in A12 are deleted. All parenteral solutions of electrolytes should be classified in B05B or in B05X.
Last updated: 2023-12-15